Pacira BioSciences, Inc. (PCRX) Earnings History
Earnings Pressure18 years of earnings data (2008–2025) · 5-year EPS trend is negative
Loading earnings history...
Pacira BioSciences, Inc. (PCRX) Earnings Overview
As of June 22, 2026, Pacira BioSciences, Inc. (PCRX) reported trailing twelve-month net income of $9M, reflecting +107.4% year-over-year growth. The company earned $0.23 per diluted share over the past four quarters, with a net profit margin of 1.0%.
Looking at the long-term picture, PCRX's 5-year EPS compound annual growth rate (CAGR) stands at -45.5%, signaling declining earnings. The company achieved its highest annual net income of $146M in fiscal 2020.
Pacira BioSciences, Inc. maintains positive profitability with a gross margin of 79.4%, operating margin of 4.6%, and net margin of 1.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), BHC (-$1.19B net income, 1.5% margin), SUPN (-$29M net income, -5.4% margin), PCRX has outperformed on profitability metrics. Compare PCRX vs PRGO →
PCRX Earnings vs Peers
Earnings metrics vs comparable public companies
PCRX Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7M | +107.1% | $33M | $0.16 | 1.0% | 4.6% |
| 2024 | -$100M | -337.3% | -$73M | $-2.15 | -14.2% | -10.5% |
| 2023 | $42M | +163.7% | $88M | $0.89 | 6.2% | 13.0% |
| 2022 | $16M | -62.1% | $60M | $0.34 | 2.4% | 9.0% |
| 2021 | $42M | -71.2% | $90M | $0.92 | 7.8% | 16.6% |
| 2020 | $146M | +1421.0% | $46M | $3.33 | 33.9% | 10.8% |
| 2019 | -$11M | -2238.9% | $10M | $-0.27 | -2.6% | 2.5% |
| 2018 | $-471,000 | +98.9% | $16M | $-0.01 | -0.1% | 4.7% |
| 2017 | -$43M | -12.3% | -$25M | $-1.07 | -14.9% | -8.7% |
| 2016 | -$38M | -2144.7% | -$32M | $-1.02 | -13.7% | -11.6% |
| 2015 | $2M | +113.5% | $9M | $0.04 | 0.7% | 3.8% |
| 2014 | -$14M | +78.5% | -$5M | $-0.39 | -6.9% | -2.6% |
| 2013 | -$64M | -22.2% | -$53M | $-1.93 | -74.7% | -62.3% |
| 2012 | -$52M | -20.7% | -$49M | $-1.72 | -133.8% | -126.1% |
| 2011 | -$43M | -59.6% | -$39M | $-2.64 | -276.2% | -249.2% |
| 2010 | -$27M | +14.4% | -$22M | $-1.58 | -186.4% | -153.6% |
| 2009 | -$32M | +24.3% | -$29M | $-55.32 | -211.3% | -190.2% |
| 2008 | -$42M | - | -$45M | $-79.23 | -300.6% | -325.8% |
Download Data
Export PCRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PCRX — Frequently Asked Questions
Quick answers to the most common questions about buying PCRX stock.
What is PCRX earnings per share (EPS)?
PCRX trailing twelve-month (TTM) diluted EPS is $0.23, reflecting +107.4% year-over-year growth. The 5-year EPS CAGR is -45.5%. Complete EPS history from 2008 to 2025 is available in the table on this page.
What is Pacira BioSciences, Inc.'s net income?
Pacira BioSciences, Inc. (PCRX) trailing twelve-month net income is $9M as of 2025. Earnings grew +107.4% year-over-year.
Is PCRX profitable?
Yes, PCRX is profitable with a TTM net income of $9M and a net profit margin of +1.0%.
What is PCRX's earnings growth rate?
PCRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: -22.2%, 5-Year: -45.5%, 10-Year: +14.9%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.
What are PCRX's profit margins?
Pacira BioSciences, Inc. net profit margin is +1.0%, operating margin is +4.6%, and gross margin is +79.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is +1.0%.
Is PCRX growing earnings?
Yes, PCRX earnings are accelerating — EPS growth of +107.4% exceeds the 5-year CAGR of -45.5%. TTM net income reached $9M. Earnings momentum is strengthening.
What was PCRX's best earnings year?
Pacira BioSciences, Inc.'s highest annual net income on record is $146M, achieved in fiscal year 2020. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.
What were PCRX's earnings last quarter?
PCRX's most recent reported quarter was Q1 2026. Net income was $7M with diluted EPS of $0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.